Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

Marvel Biosciences Corp. , and its wholly owned subsidiary, Marvel Biotechnology Inc. , today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel...

Related Keywords

Mark Williams ,Emmanuel Planel ,Marvel Biotechnology Inc ,Regulation Services Provider ,Alberta Newsfile Corp ,Laval University ,Marvel Biosciences Corp ,Venture Exchange ,Company Or Marvel ,Marvel Biotechnology ,Professor Emmanuel Planel ,Abnormal Tau ,Chronic Traumatic Encephalopathy ,Biosciences Corp ,Chief Executive Officer ,Chief Science ,Markets ,